Strong growth in 2005 first half adjusted EPS : up 26.1% at 2.22
Increase in full year adjusted EPS guidance Positive phase IIb/III results for 6 products
-
-
Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin
I dagens nummer av Journal of Clinical Oncology: Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin I dagens nummer av den internationella tidskriften Journal of Clinical Oncology har resultaten av den första jämförande studie av olika cellgifter publicerats. I studien jämförs två av de vanligaste cellgifterna vid behandling av avancerad bröstcancer, docetaxel
-
RESOLUTION OF UK PLAVIX® LITIGATION
Today sanofi-aventis announced that Aircoat has withdrawn the revocation action by which it had sought to invalidate the sanofi-aventis patent in the UK claiming clopidogrel bisulfate. Aircoats revocation action was originally announced in January 2005. About sanofi-aventis Sanofi-aventis is the worlds 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&
-
SANOFI-AVENTIS SELLS ITS INTERESTS IN WACKER-CHEMIE
- Hoechst AG, a subsidiary of sanofi-aventis, and the Wacker family agreed on the restructuring of the ownership of Wacker-Chemie GmbH.
-
Allegra-D® 24 hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets now available in the United-States for seasonal allergy sufferers
Allegra-D® 24 hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets now available in the United-States for seasonal allergy sufferers Läs mer http://en.sanofi-aventis.com/index.asp
-
Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis
Läs mer på http://en.sanofi-aventis.com/press/p_press.asp
-
Strong net sales growth in the first half of 2005
Strong net sales growth in the first half of 2005: 11.0% on a comparable basis. Further increase in market share in the second quarter.
-
TRANSFER OF COMMERCIAL RIGHTS OF PLAVIX® IN JAPAN TO SANOFI-AVENTIS
- Sanofi-aventis and Daiichi Pharmaceutical Co., Ltd. announced today the transfer of all commercial rights for Plavix® (clopidogrel) in Japan from Daiichi and a jointly held partnership to sanofi-aventis Japan. The transfer will be implemented in conformity with local regulatory requirements. Given their long-standing partnership, both parties agreed to collaborate in the future in the areas
-
PANEL OF EXPERTS AGREE THAT BONE MINERAL DENSITY IS NO LONGER ENOUGH
Understanding the Factors Which Contribute to Bone Strength Geneva, Switzerland, 28 June, 2005 The Alliance for Better Bone Health announced today that according to evidence presented by an international panel of osteoporosis experts, Bone Mineral Density (BMD) testing does not accurately reflect all factors important to bone strength. The panels findings, presented at the Second Joint Meetin
-
A high proportion of hypertensive patients achieved blood pressure treatment goal with irbesartan-based combination therapy, findings show
Contact: sanofi-aventis Jean Marc Podvin +33 (0)1 53 77 42 23 Salah Mahyaoui +33 (0)1 53 77 40 31 +33 (0)6 73 68 78 88 Bristol-Myers Squibb Rob Hutchinson +1 609 252 3901 +1 609 271 2704 Recent clinical findings have demonstrated that a large majority of hypertensive patients who failed to achieve blood pressure goal on monotherapy can be helped to attain goal with the angiotensin-I
-
Lovenox® Patent Trial Update
On June 15, 2005, the U.S. District Court for the Central District of California granted the Motion for Summary Judgment for inequitable conduct filed by Amphastar Pharmaceuticals, Inc. in the sanofi-aventis Groups suit against Amphastar and Teva Pharmaceuticals USA, Inc. for infringement of US Patent no. 5,389,618 ('618 patent") by their proposed generic versions of Lovenox®. A formal entry o
-
Visa mer
Loading...